KEFZOL

Post-LOE

cefazolin sodium

Teva

ANDAINJECTIONINJECTABLE

Approved

Nov 1973

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

KEFZOL (cefazolin sodium) by Teva is 12. Approved for respiratory tract infections due to streptococcus pneumoniae, staphylococcus aureus, streptococcus pyogenes in adults and 14 more indications. First approved in 1973.

Drug data last refreshed 18h ago

Mechanism of Action

12.1 Mechanism of Action Cefazolin is an antibacterial drug [ see ]. 12.2 Pharmacodynamics The pharmacokinetic/pharmacodynamic relationship for cefazolin has not been evaluated in patients. 12.3 Pharmacokinetics Studies have shown that following intravenous administration of cefazolin to normal…

Worked on KEFZOL at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

KEFZOL

Mechanism of Action

Indications (17)